Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02119676 · ClinicalTrials.gov registry record · Phase 2
Study of Ruxolitinib in Colorectal Cancer Patients
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 396
- Enrollment target
NCT02119676: Clinical Trial Phase 2 study, sponsored by Incyte Corporation.
NCT02119676 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 396 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (198% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02119676, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 396 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.
Primary Outcome
Overall survival is defined as the time from randomization to death due to any cause. Participants without death observed at the time of the analysis will be censored at last date known to be alive. The median overall survival time was estimated using the Kaplan-Meier method. Overall survival was compared between treatment groups using log-rank test.
Interventions
- DRUG Placebo
- DRUG Regorafenib
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Why NCT02119676 stopped before completion
NCT02119676 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (198% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02119676 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02119676 about?
NCT02119676 is a clinical study titled "Study of Ruxolitinib in Colorectal Cancer Patients". The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.
What is the current status of trial NCT02119676?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 2014-03. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02119676?
The interventions under investigation include: Placebo (DRUG), Regorafenib (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT02119676?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02119676's enrollment target sits among peer trials
396 103rd of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia